Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update

Demirci E., Kabasakal L., Toklu T., Ocak M., Şahin O. A., Alan-Selcuk N., ...Daha Fazla

NUCLEAR MEDICINE COMMUNICATIONS, cilt.39, sa.8, ss.789-796, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 39 Sayı: 8
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1097/mnm.0000000000000874
  • Dergi Adı: NUCLEAR MEDICINE COMMUNICATIONS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.789-796
  • Anahtar Kelimeler: Lu-177-DOTATATE, neuroendocrine tumours, octreotide, peptide receptor radionuclide therapy, radionuclide therapy, somatostatin, RECEPTOR RADIONUCLIDE THERAPY, PHASE-II, MIDGUT, NEOPLASMS, CARCINOMAS, OCTREOTIDE, EXPRESSION, TOXICITY, EFFICACY, TRIAL
  • İstanbul Üniversitesi Adresli: Evet

Özet

Purpose Upon diagnosis, distant metastases are encountered in 21-50% of neuroendocrine tumours (NETs). However, few systemic treatment options are available for the well-differentiated NETs in the metastatic stage. Lu-177-DOTATATE is one of the most effective treatments in this limited patient group. We retrospectively investigated its efficacy and effect on the survival in patients with both well-differentiated and grade III NETs who had high uptake in pretherapeutic Ga-68-DOTATATE PET/computed tomography scans.